Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF

NCT07630454 on ClinicalTrials.gov · last registry update 2026-06-05

An unusually large phase 4: 602 participants, more than double the 75 typical for the stage. Due to report 1 August 2029, alongside 12 other tracked readouts that quarter. Primary outcome, as filed: Number of Participants With Recurrence of atrial fibrillation, atrial flutter, or atrial tachycardia. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is approved in the US, but not for atrial fibrillation and heart failure — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: NOT_YET_RECRUITING
Phase: P4
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Yunlong Wang
Sponsor type: Other
Enrollment: 602
Started: 2026-08-01
Primary completion: 2029-08-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Number of Participants With Recurrence of atrial fibrillation, atrial flutter, or atrial tachycardia

Conditions studied

Atrial Fibrillation · Heart Failure With Preserved Ejection Fraction (HFpEF) · Tirzepatide

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.